1WALDHERR C,PLESS M,MAECKE HR,et al.The clinical value of[^90Y-DOTA]-D-Phe^1-Tyr^3-octreotide (^90Y-DOTATOC) in the treatment of neuroendocrine tumours:A clinical phase Ⅱ study[J].Ann Oncol,2001,12(7):941-945.
2KWEKKEBOOM D J,DE HERDER W W,KAM B L,et al.Treatment with the radiolabeled somatostatin analog[^177Lu-DOTA0,Tyr^3]octreotate:toxicity,efficacy,and survival[J].J Clin Oncol,2008,26(13):2 124-2 130.
3NAYAK T K,NORENBERG J P,ANDERSON T L,et al.Somatostatin-receptor-targeted alpha-emitting ^213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells[J].Nucl Med Biol,2007,34(2):185-193.
4NAYAK T K,NORENBERG J P,ANDERSON T L,et al.Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells[J].Nucl Med Biol,2007,34(2):185-193.
5INJ M,CHEN J H,WALTER M A,et al.Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy[J].Clin Can Res,2005,11(3):1 136-1 145.
6GINJ M,ZHANG H W,EISENWIENER K P,et al.New pansomatostatin ligands and their chelated versions:affinity profile,agonist activity,internalization,and tumor targeting[J].Clin Can Res,2008,14(7):2 019-2 027.
7CAPELLO A,KRENNING E P,BERNARD B F,et al.Increased cell death after therapy with an arg-gly-asp-linked somatostatin analog[J].J Nucl Med,2004,45(10):1 716-1 720.
8CAPELLO A,KRENNING E P,BERNARD B F,et al.Anticancer activity of targeted proapoptotic peptides[J].J Nucl Med,2006,47(1):1 122-1 129.
9GINJ M,HINNI K,TSCHUMI S,et al.Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters[J].J Nucl Med,2005,46(12):12 2097-12 2103.
10GRAHAM K,WANG Q,BOY R G,et al.Synthesis and evaluation of intercalating somatostatin receptor binding peptide conjugates for endoradiotherapy[J].J Pharm Pharmaceut Sci,2007,10(2):286-297.
